Lisaftoclax (APG-2575) Clinical Trials
4 recruitingDrug
Phase 22Phase 32Phase 11
Showing 1–4 of 4 trials
Recruiting
Phase 1Phase 2
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
Ascentage Pharma Group Inc.682 enrolled12 locationsNCT04501120
Recruiting
Phase 2
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
Mantle Cell Lymphoma (MCL)
Ruijin Hospital25 enrolled1 locationNCT07272499
Recruiting
Phase 3
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Ascentage Pharma Group Inc.490 enrolled2 locationsNCT06641414
Recruiting
Phase 3
A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
CLL/SLL
Ascentage Pharma Group Inc.344 enrolled6 locationsNCT06319456